期刊文献+

早期糖尿病肾病患者血清鸢尾素、高迁移率族蛋白Box1、神经调节蛋白4水平变化及临床意义

Changes in Serum Irisin,High Mobility Group Box 1,and Neuregulin 4 Levels in Patients with Early Diabetic Kidney Disease and Their Clinical Significance
下载PDF
导出
摘要 目的探讨早期糖尿病肾病(DKD)患者血清鸢尾素、高迁移率族蛋白B1(HMGB1)、神经调节蛋白4(NRG4)水平变化及临床意义。方法选取2022年3月至2024年3月郑州大学第一附属医院收治的80例早期DKD患者作为早期DKD组,选取同期50例健康体检人员作为健康对照组,对两组人口学特征、临床资料进行收集,对血清鸢尾素、HMGB1、NRG4水平进行检测,进行单因素与多因素Logistic回归分析,明确早期DKD发生的危险因素。结果两组患者年龄、性别、饮酒史、冠心病史、吸烟史、高血压史、舒张压、收缩压、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平比较差异无统计学意义(P>0.05);早期DKD组的血清鸢尾素、NRG4水平更低,HMGB1水平更高,差异均有统计学意义(P<0.05);多因素二元Logistic回归分析结果显示,血清鸢尾素(OR=0.568;95%CI:0.389~0.829)、NRG4(OR=0.456;95%CI:0.246~0.845)是影响早期DKD发生的保护性因素,差异具有统计学意义(P<0.05),HMGB1(OR=2.976;95%CI:2.664~3.325)是独立危险因素,差异具有统计学意义(P<0.05)。结论早期DKD患者血清鸢尾素、NRG4水平更低,HMGB1水平更高,临床可用血清鸢尾素、HMGB1、NRG4水平对早期DKD发生进行评估。 Objective To investigate the changes in serum irisin,high mobility group box 1(HMGB1),and neuregulin 4(NRG4)levels in patients with early diabetic kidney disease(DKD)and their clinical significance.Methods A total of 80 patients with early DKD treated at the first affiliated hospital of zhengzhou university from March 2022 to March 2024 were selected as the early DKD group,and 50 healthy individuals undergoing physical examination during the same period were selected as the healthy control group.Demographic characteristics and clinical data of the two groups were collected,and serum irisin,HMGB1,and NRG4 levels were measured.Univariate and multivariate logistic regression analyses were performed to identify risk factors for early DKD.Results There were no statistically significant differences in age,gender,history of alcohol consumption,history of coronary heart disease,history of smoking,history of hypertension,diastolic blood pressure,systolic blood pressure,high-density lipoprotein cholesterol(HDL-C),and low-density lipoprotein cholesterol(LDL-C)levels between the two groups(P>0.05).The early DKD group had lower serum irisin and NRG4 levels and higher HMGB1 levels,with statistically significant differences(P<0.05).Multivariate binary logistic regression analysis showed that serum irisin(OR=0.568;95%CI:0.389~0.829)and NRG4(OR=0.456;95%CI:0.246~0.845)were protective factors for early DKD,with statistically significant differences(P<0.05),while HMGB1(OR=2.976;95%CI:2.664~3.325)was an independent risk factor,with a statistically significant difference(P<0.05).Conclusion Patients with early DKD have lower serum irisin and NRG4 levels and higher HMGB1 levels.Serum irisin,HMGB1,and NRG4 levels can be used to assess the occurrence of early DKD.
作者 连艳珍 李文悌 LIAN Yanzhen;LI Wenti(Department of Laboratory Medicine,The First Affiliated Hospital of Zhengzhou University,Zhengzhou Henan 450000,China)
出处 《临床研究》 2024年第9期133-136,共4页 Clinical Research
关键词 早期糖尿病肾病 血清鸢尾素 高迁移率族蛋白Box1 神经调节蛋白4 临床意义 early diabetic kidney disease serum irisin high mobility group box 1 neuregulin 4 clinical significance
  • 相关文献

参考文献18

二级参考文献138

  • 1郭飞飞,黄永杰,郑红霞,谢林森.血清Cys-c、25(OH)D、Hcy联合检测对2型糖尿病肾病患者的临床诊断价值[J].慢性病学杂志,2021(7):1055-1057. 被引量:4
  • 2Montserrat B Duran-Salgado,Alberto F Rubio-Guerra.Diabetic nephropathy and inflammation[J].World Journal of Diabetes,2014,5(3):393-398. 被引量:178
  • 3Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey[J]. Lancet, 2012,379(9818):815-822.
  • 4Parving HH, Lewis JB, Ravid M, et al. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective[J]. Kidney Int, 2006,69(11):2057-2063.
  • 5Liu ZH. Nephrology in China[J]. Nat Rev Nephrol, 2013,9(9):523-528.
  • 6Woodward M, Patel A, Zoungas S, et al. Does glycemic control offer similar benefits among patients with diabetes in different regions of the world? Results from the ADVANCE trial[J]. Diabetes Care, 2011,34(12):2491-2495.
  • 7Zhuo L, Zou G, Li W, et al. Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patients with type 2 diabetes mellitus[J]. Eur J Med Res, 2013,18:4.
  • 8KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J]. Am J Kidney Dis, 2007,49(2 Suppl 2):S12-S154.
  • 9American Diabetes Association. Standards of medical care in diabetes--2014[J]. Diabetes Care, 2014,37(Suppl 1):S14-S80.
  • 10KDOQI. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease[J]. Kidney Int Suppl, 2013,3(1):1-150.

共引文献453

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部